RecruitingNCT01241305

One-Time DNA Study for Vasculitis

VCRC Genetic Repository One-Time DNA Protocol


Sponsor

University of Pennsylvania

Enrollment

1,000 participants

Start Date

Oct 1, 2010

Study Type

OBSERVATIONAL

Conditions

Summary

The purpose of this study is to identify genes that increase the risk of developing vasculitis, a group of severe diseases that feature inflammation of blood vessels. Results of these studies will provide vasculitis researchers with insight into the causes of these diseases and generate new ideas for diagnostic tests and therapies, and will be of great interest to the larger communities of researchers investigating vasculitis and other autoimmune, inflammatory, and vascular diseases.


Eligibility

Min Age: 7 Years

Inclusion Criteria47

  • \. Diagnostic criteria for Giant Cell Arteritis Age at disease onset \>50 years (required)
  • New onset or new type of localized pain in the head
  • Temporal artery abnormality (i.e. temporal artery tenderness to palpation or decreased pulsation, unrelated to arteriosclerosis of cervical arteries)
  • ESR of \>40mm in the first hour by the Westergren method
  • Abnormal artery biopsy (i.e. temporal artery biopsy showing vasculitis characterized by a predominance of mononuclear cell infiltration or granulomatous inflammation, usually with multinucleated giant cells)
  • Large Vessel Vasculitis (LVV) by angiogram or biopsy not explained by something else
  • \. Diagnostic criteria for Takayasu's Arteritis
  • Age at disease onset \<50 years
  • Claudication of extremities
  • Decreased brachial artery pulse (one or both arteries)
  • Blood pressure difference of \>10mm Hg between the arms
  • Bruit over subclavian arteries or aorta
  • Arteriogram abnormalities compatible with TAK (includes conventional dye angiography or MR angiography or CT angiography)
  • \. Diagnostic criteria for Polyarteritis Nodosa Major criteria (not explained by other causes) felt by investigator to be due to vasculitis
  • Arteriographic abnormality
  • Presence of granulocyte or mixed leukocyte infiltrate in an arterial wall on biopsy
  • Mononeuropathy or polyneuropathy
  • Minor criteria (not explained by other causes) felt by investigator to be due to vasculitis
  • Weight loss \> 4 kg
  • Livedo reticularis, cutaneous ulcerations, or skin nodules
  • Testicular pain or tenderness
  • Myalgias
  • Diastolic blood pressure \> 90 mm Hg
  • Elevated BUN or serum creatinine levels
  • Ischemic abdominal pain
  • Isolated cutaneous Polyarteritis Nodosa 1. Biopsy-proven cutaneous PAN
  • \. Diagnostic criteria for Granulomatosis with Polyangiitis (Wegener's) (GPA) and Microscopic Polyangitis (MPA)
  • Diagnosis of GPA or MPA. Widely accepted diagnostic criteria, as opposed to classification criteria or definitions, have not been developed for GPA \& MPA.
  • For diagnosis of GPA meets at least 2 of the following 5 modified ACR criteria:
  • Nasal or oral inflammation with oral ulcers or nasal discharge with pus or blood
  • Abnormal chest radiograph with nodules, fixed infiltrates, or cavities
  • Urinary sediment with microhematuria or red cell casts
  • Granulomatous inflammation within the wall of an artery or in the perivascular area on biopsy
  • Antineutrophil cytoplasmic antibody (ANCA) positive by enzyme immunoassay for either PR3- or MPO-ANCA
  • For diagnosis of MPA, meets the Chapel Hill Consensus Conference Definition for MPA:
  • Necrotizing vasculitis, with few or no immune deposits, that affects small vessels (i.e., capillaries, venules, arterioles)
  • Necrotizing arteritis involving small- and medium-sized arteries may be present
  • Necrotizing glomerulonephritis is very common
  • Pulmonary capillaritis often occurs
  • \. Diagnostic criteria for Eosinophilic Granulomatosis with Polyangiitis (Churg-Strauss)
  • Asthma
  • Peak peripheral blood eosinophilia of \>10% of total WBC
  • Peripheral neuropathy attributable to vasculitis
  • Transient pulmonary infiltrates on chest imaging studies
  • Paranasal sinus abnormalities or nasal polyposis
  • Eosinophilic inflammation on tissue biopsy
  • If patients have 4 of the above 6 criteria but lack clearcut documentation of small vessel vasculitis, they are also eligible for enrollment.

Exclusion Criteria3

  • Inability to give informed consent and to sign the consent form
  • Enrolled in VCRC protocols 5502, 5503, 5504, 5505, 5506, 5522, or 5523
  • Unwilling to provide blood for DNA collection

Interested in this trial?

Get notified about updates and connect with the research team.


Locations(14)

Cedars-Sinai Medical Center

Los Angeles, California, United States

University of California, San Francisco

San Francisco, California, United States

Northwestern University

Chicago, Illinois, United States

University of Kansas Medical Center

Kansas City, Kansas, United States

University of Michigan

Ann Arbor, Michigan, United States

Mayo Clinic

Rochester, Minnesota, United States

Hospital for Special Surgery

New York, New York, United States

Cleveland Clinic

Cleveland, Ohio, United States

University of Pennsylvania

Philadelphia, Pennsylvania, United States

University of Pittsburgh

Pittsburgh, Pennsylvania, United States

University of Utah

Salt Lake City, Utah, United States

St. Joseph's Healthcare

Hamilton, Ontario, Canada

Mount Sinai Hospital

Toronto, Ontario, Canada

Istanbul University

Istanbul, Fatih, Turkey (Türkiye)

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT01241305


Related Trials